Skip to main
ELEV
ELEV

Elevation Oncology (ELEV) Stock Forecast & Price Target

Elevation Oncology (ELEV) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Elevation Oncology Inc. is positioned favorably due to its innovative product candidate, EO-3021, which demonstrates promising preliminary data, including a good objective response rate (ORR) of 43% in a selectively targeted patient population with the Claudin 18.2 biomarker. Upcoming data catalysts, including additional monotherapy results and first-in-human combination therapy data, could significantly enhance investor confidence and facilitate access to further capital, strengthening the company's financial position. Additionally, the potential for EO-3021 to provide a superior treatment option in combination therapies, as evidenced by its favorable safety profile and efficacy compared to established regimens, indicates a strong strategic advantage in the competitive oncology market.

Bears say

Elevation Oncology Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily stemming from its inability to effectively defend its portfolio, which raises concerns about potential market share loss for its product candidates. The company's struggles with accessing capital may hamper critical business operations, prolonging the timeline to profitability and cash flow generation. Additionally, recent unfavorable clinical trial data, particularly regarding the efficacy of EO-3021 in low-expressing Claudin 18.2 patient populations, alongside the absence of revenues and significant net losses, further exacerbate investor apprehensions about the company's financial health and future prospects.

Elevation Oncology (ELEV) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevation Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevation Oncology (ELEV) Forecast

Analysts have given Elevation Oncology (ELEV) a Hold based on their latest research and market trends.

According to 9 analysts, Elevation Oncology (ELEV) has a Hold consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevation Oncology (ELEV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.